Fredun Pharmaceuticals Reports Positive Financial Results for Q1 FY25, Stock Given 'Hold' Rating by MarketsMOJO

Fredun Pharmaceuticals, a microcap company in the pharmaceutical industry, has recently announced its financial results for the quarter ending June 2024. The company’s stock has been given a ‘Hold’ call by MarketsMOJO.

According to the financial report, Fredun Pharma has shown a positive performance in the quarter, with a score of 9 out of 10, compared to 4 in the previous quarter. This indicates a significant improvement in the company’s financials.

One of the key factors contributing to this positive performance is the growth in Profit After Tax (PAT), which has increased by 72.1% year on year to Rs 4.13 crore. The trend for PAT in the near term is also very positive. Similarly, the Net Sales for the quarter have grown by 27.03% year on year to Rs 78.82 crore, with a positive sales trend in the near term. Additionally, the Profit Before Tax less Other Income (PBT) has also shown a growth of 35.29% year on year to Rs 5.52 crore, with a positive trend in the near term.

However, one area of concern for Fredun Pharma is the rising interest cost, which has increased by 24.14% over the previous half-yearly period to Rs 8.28 crore. This signifies an increase in borrowings for the company.

Overall, Fredun Pharmaceuticals has shown a positive financial performance in the quarter ending June 2024, with growth in key areas such as PAT, Net Sales, and PBT. However, the company needs to keep an eye on its interest cost to maintain its positive trend. Investors are advised to hold their stocks in Fredun Pharma, as recommended by MarketsMOJO.